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Abstract
Purpose: Near real‐time vaccine safety surveillance (NRTVSS) using electronic health records
has been used to detect timely vaccine safety signals. Trial implementation of NRTVSS using the
Clinical Practice Research Datalink (CPRD) has shown that there is limited power to detect safety
signals for rare events. Delays in recording outcomes and receiving data influence the power and
timeliness to identify a signal. Our work aimed to compare how different sources of delays influ-
ence power and expected time to signal to implement NRTVSS using CPRD.
Methods: We studied seasonal influenza vaccine/Guillain‐Barré syndrome and performed
power and expected time to signal calculations for the 2013‐2014/2014‐2015 seasons. We used
the Poisson‐based maximised sequential probability ratio test, which compares observed‐to‐
expected events. For each study season, we obtained an average Guillain‐Barré syndrome/sei-
zures age‐sex–adjusted rate from the 5 previous seasons and then used this rate to calculate
the expected number of events, assuming a 42‐day risk‐window. Calculations were performed
for detecting rate ratios of 1.5 to 10. We compared power and timeliness considering combina-
tions of the presence/absence of delays in recording outcomes and in receiving data. The R‐pack-
age Sequential was used.
Results: In general, there was ≥80% power to detect increases in risk of ≥4 at the end of the
season. Assuming absence of delays slightly improved power (a maximum increase of 4%) but did
not noticeably reduce time to detect a signal.
Conclusion: Removing delays in data availability is insufficient to significantly improve the
performance of a NRTVSS system using CPRD. Expansion of CPRD data is required.
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1 | INTRODUCTION
Near real‐time vaccine safety surveillance (NRTVSS) is an option in the
post‐licensure vaccine safety toolkit. Near real‐time vaccine safety
surveillance is usually initiated soon after a new vaccine is introduced,
and data from electronic heath records are examined at regular points
in time. This helps with timely detection of safety signals.1
Near real‐time vaccine safety surveillance has not been fully
implemented in the UK, but our recent study trialling NRTVSS imple-
mentation using data from the Clinical Practice Research Datalink
(CPRD) showed it is possible to implement a system.2 Nevertheless,
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system performance (including power and expected time to signal) to
identify a rare outcome (Guillain‐Barré syndrome, GBS) following sea-
sonal influenza was not optimal. In particular, using the most powerful
test (Poisson‐based maximised probability ratio test, PMaxSPRT), there
was power of ≥80% to identify a fourfold increase in risk, and a signal
would be detected 3 months after the start of surveillance. It is thus
important to understand what factors affect power and expected time
to signal and what changes to currently available data might improve
the ability to identify signals rapidly using CPRD.
If PMaxSPRT is used, the expected number of events at the end of
the surveillance period dictates power and expected time to signal. The
expected number of events is a function of the data available, depend-
ing on both the number of individuals contributing data (the volume of
data) and on delays in data availability. Clinical Practice Research
Datalink is a primary care database, and the volume of data is deter-
mined by the number of practices and patients contributing data.
Delays can occur in (i) identifying a condition after the initial consulta-
tion, (ii) recording a condition diagnosed outside the practice (e.g. in
hospital), (iii) practices uploading their data to CPRD, and (iv)
researchers receiving data for analysis. Previous work assessing delays
due to (ii) showed that, for selected conditions of interest regarding
vaccine safety, records accrue within a month of the deemed date of
diagnosis.3 Regarding (iii) and (iv), CPRD data are made available to
researchers monthly and practices upload data prior to this, with the
last collection date from each practice recorded in CPRD.
Clinical Practice Research Datalink is a dynamic database, and new
practices may start contributing data. Additionally, changes to the
mode of data collection from practices and frequency of data releases
could reduce delays. Both expansion and reduction of delays could
improve NRTVSS system performance. We sought to assess how
delays influenced power and expected time to signal, to inform data
providers on how decreasing delays could improve performance of a
NRTVSS system. As a secondary objective, we further assessed the
performance of a system based on data available around the middle
of the surveillance period for a short vaccine programme of fixed
length, to understand what could be detected at a time when it would
still be possible to implement measures to minimise risks.
2 | METHODS
We used data from our previous study that evaluated the feasibility of
implementing a NRTVSS system. Here, we provide a brief summary of
the methods used to obtain those data (for further information see
Leite et al2). Additionally, we explain how we assessed the influence
of delays on power and expected time to signal, the main focus of this
report.
2.1 | Data source
We used CPRD, a UK database containing anonymised primary care
records from individuals registered with participating practices (6.9%
of the population). Information is Read‐coded, including demographics,
diagnoses, therapies, vaccinations, health‐related behaviours, and
referrals to and feedback from hospital.4 Clinical Practice Research
Datalink also contains information of when a patient joined and left a
practice (current registration date and transfer out date, respectively),
when a practice met certain requirements necessary for it to be con-
sidered of research quality (up‐to‐standard) and when information
was last collected from each practice (last collection date, available in
each monthly update).4
2.2 | Vaccine/outcome pairs and study period
Our original study evaluated seasonal influenza vaccine/GBS and
mumps‐measles‐rubella vaccine/seizures. As there was sufficient
power to detect a twofold increase in risk for mumps‐measles‐rubella
vaccine/seizures, we considered the performance of the system for
this pair was satisfactory. We thus only assessed the influence of
delays for seasonal influenza/GBS. We included individuals aged
≥65 years and studied seasons 2013/2014 and 2014/2015, using data
released in July 2015 and 2016, respectively.
2.3 | Analysis
We used continuous PMaxSPRT as it is the most powerful test, and
CPRD provides data in a near‐continuous fashion (monthly).5 The number
of expected events was obtained based on the average GBS age‐sex–
specific rate from the 5 seasons prior to the study seasons (2008‐2013
and 2009‐2014), considering a 42‐day post‐vaccination risk‐window.
We applied the historical rates to the follow‐up time in the study
periods to obtain the expected number of events. Start of follow‐up
time was the latest of the up‐to‐standard date, current registration
date (plus 1 year to exclude retrospective recording of events when
registering with a new practice6), the beginning of the study period,
and the start of the risk‐window. End of follow‐up was the earliest of
the patient's transfer out date, the practice's last collection date, end
of the study period, or end of the risk‐window.
The number of expected events was calculated in slightly different
ways, to consider different delay scenarios (see below). Based on
these numbers, we calculated power and expected time to signal (per-
formance measures), assuming a range of plausible rate ratios (1.5‐10),
KEY POINTS
• The Clinical Practice Research Datalink (CPRD) can be
used to implement near real‐time vaccine safety
surveillance, but there is limited power to detect
signals for rare outcomes.
• Delays in recording outcomes and in receiving data
might limit power and timeliness of a system. We
assessed the influence of these sources of delays to
inform data providers of the steps required to improve
a system using CPRD data.
• Removing delays in recording outcomes and receiving
data is unlikely to significantly improve the
performance of a system using CPRD data. Expansion
of the data available is needed.
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a level of significance of 5%, and stipulating a minimum of 1, 2, or 4
events before raising a signal. Calculations were performed using the
R package Sequential.7
We assessed the influence of delays on system performance by cal-
culating follow‐up time (hence, the expected number of events) assuming
the system had different combinations of presence/absence of delays in
recording outcomes and in receiving data. Additionally, we looked at
performance measures assuming analyses ended at the mid‐season
(December release). Ending surveillance earlier might increase power as
less sequential tests are performed, but the number of expected events
is likely to be lower (due to less data available), thus reducing power.
The delay scenarios assessed are presented in Table 1. The scenario
considering both sources of delays was used as a reference, as this
corresponded to what we did for the test implementation.2
For delays in recording outcomes, we considered the follow‐up
time for the patients as explained above (absence of delays) and then
adjusted this follow‐up time to account for delays, by reducing the
expected number of events based on the historical delays' distribution
(presence of delays).
For delays in receiving data, we included all data available for the
study period regardless of when these data were received (absence
of delays) and then included only data received by the end of the sur-
veillance period (presence of delays). We identified data received by
the end of surveillance by using the last collection date in that data
release. For the reference scenario, we considered the last collection
dates available in the April 2014 and April 2015 releases for season
2013/2014 and 2014/2015, respectively. Similarly, we used the last
collection dates available in the December releases (2013 and 2014
for season 2013/2014 and 2014/2015, respectively) when assessing
performance at the mid‐season (scenario 3).
3 | RESULTS
Table 2 presents the results of our calculations. In general, there was
≥80% power to detect increases in risk of ≥4 at the end of the season.
Removing sources of delays improved power by 1% to 4% and would
allow detection of a signal at the same release of the implementation
scenario. Stopping surveillance around mid‐season (scenario 3)
resulted in substantial reductions in power, particularly to detect
medium (3‐6 fold) increases in risk. For this scenario, there was ≥80%
power to detect an increase in risk of 8 to 10. If there was a signal, this
would be detected by early December.
4 | DISCUSSION
We analysed the impact of delays in data availability on NRTVSS
implementation using CPRD as a way to inform data providers about
measures that could improve performance of a NRTVSS system. Our
results showed that delays affect power, but only slightly. There
were almost no differences observed in the expected time to signal,
even when there were improvements in power. Removing delays
would thus be insufficient to improve the performance of a system
using CPRD data, as the main limiting factor is the volume of data
available.
The small differences between each scenario are probably related
to the performance measures being calculated on the basis of
expected events at the end of the surveillance period. Most individuals
are vaccinated at the beginning of the season, and by its end, data have
had enough time to accrue. This applies to both sources of delays.
Assessment of the performance at mid‐season revealed that we
would be able to detect only very large increases in risk at the begin-
ning of December. This raises the issue of timeliness, as by then most
individuals would have been vaccinated and any intervention might
have limited reach.
Clinical Practice Research Datalink currently collects data from
practices using VISION software, but it is expanding to include prac-
tices using EMIS software.8 Presently, there are data from 4.4 million
active patients. Initial analysis of EMIS practices indicates an additional
2.6 million active patients (Rachel Williams, personal communication).
Assuming this would translate to a similar number of expected events,
the new data would amount to approximately 3 expected events,
which would be sufficient to detect increases of threefold or more in
the risk of GBS following seasonal influenza vaccination. This might
not be enough to detect small increases in risk, particularly for rare
events. Furthermore, including data from practices using a different
software may pose new challenges. For example, the adjustment for
delays we proposed is based on the delay distribution observed using
data from VISION practices, and it might not be applicable for EMIS
practices.3 Including EMIS practices in a NRTVSS will thus require
additional exploration of these data.
In our work, we considered a power of ≥80% as a satisfactory per-
formance. However, GBS can be a severe condition, and when
implementing a system, it may be necessary to require higher power
level to detect more serious conditions (such as 90%). For existing
CPRD data, requirement of 90% power would mean that we could only
accurately identify increases in risk ≥5.
TABLE 1 Combination of delays assessed under each scenario
Scenario—Source of
Delays
Delays
End of Surveillance CommentsRecording Receiving
Recording/receiving (reference) + + April data release
(end of season)
Corresponds to the way NRTVSS was implemented using CPRD data.
Reference scenario
1. None − − April data release
(end of season)
Ideal scenario; events are recorded as they happen and data are
available immediately
2. Recording + − April data release
(end of study period)
Mimics a situation where CPRD receives data on a daily basis and
makes it available straight away
3. Recording/receiving + + December data release Corresponds to the reference scenario but considering data available
until December
Abbreviations: CPRD, Clinical Practice Research Datalink; NRTVSS, near real‐time vaccine safety surveillance.
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TABLE 2 Expected number of events, power, and expected time to signal under different combination of delays
Minimum
events RR
Delay Scenario
Reference Scenario 1 Scenario 2 Scenario 3
Season 2013‐2014
Expected number of events
— — 1.89 2.09 1.94 0.62
Power (expected time to signal in terms of data release)
1 1.5 13 13 13 10
2 25 26 25 16
2.5 40 42 40 22
3 55 (J) 58 (J) 55 (J) 30
4 78 (J) 81 (J) 79 (J) 44
5 91 (D) 93 (J) 92 (D) 58 (D)
6 97 (D) 98 (D) 97 (D) 69 (D)
8 100 (D) 100 (D) 100 (D) 85 (D)
10 100 (D) 100 (D) 100 (D) 93 (D)
2 1.5 14 15 15 11
2 28 30 29 18
2.5 44 46 45 27
3 60 (J) 62 (J) 61 (J) 35
4 82 (J) 84 (J) 83 (J) 52 (D)
5 93 (D) 95 (D) 94 (D) 65 (D)
6 98 (D) 98 (D) 98 (D) 76 (D)
8 100 (D) 100 (D) 100 (D) 89 (D)
10 100 (D) 100 (D) 100 (D) 96 (D)
4 1.5 16 17 16
2 33 34 33
2.5 50 (J) 52 (J) 50 (J)
3 65 (J) 68 (J) 66 (J)
4 86 (J) 88 (J) 86 (J) a
5 95 (J) 96 (J) 95 (J)
6 98 (J) 99 (J) 99 (J)
8 100 (D) 100 (D) 100 (D)
10 100 (D) 100 (D) 100 (D)
Season 2014‐2015
Expected number of events
— — 1.66 1.84 1.69 0.38
Power (expected time to signal in terms of data release)
1 1.5 12 13 12 9
2 23 25 24 13
2.5 37 40 37 18
3 51 (J) 55 (J) 52 (J) 23
4 74 (J) 78 (J) 75 (J) 34
5 88 (J) 91 (J) 89 (J) 44
6 95 (J) 97 (J) 96 (J) 54 (D)
8 99 (D) 100 (D) 100 (D) 70 (D)
10 100 (D) 100 (D) 100 (D) 81 (D)
2 1.5 14 14 14 10
2 26 28 26 16
2.5 41 43 41 22
3 55 (J) 59 (J) 56 (J) 29
4 77 (J) 81 (J) 78 (J) 42
5 90 (J) 93 (J) 91 (J) 53 (D)
6 96 (J) 98 (J) 96 (J) 63 (D)
8 100 (D) 100 (D) 100 (D) 78 (D)
10 100 (D) 100 (D) 100 (D) 87 (D)
4 1.5 16 16 16
2 31 33 31
2.5 47 50 (J) 48
3 62 (J) 65 (J) 63 (J)
4 83 (J) 86 (J) 84 (J) a
5 93 (J) 95 (J) 94 (J)
6 98 (J) 98 (J) 98 (J)
8 100 (J) 100 (J) 100 (J)
10 100 (J) 100 (J) 100 (J)
Abbreviations: D, December; J, January; RR, rate ratio.
aNumber of expected events is too small to calculate performance measures.
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Ourwork is subject to some limitations. Our adjustment for record-
ing delays was based on a simplification of the data accrual process and
on a historical distribution of delays. Nevertheless, previous work has
shown constant recording delay patterns during a 10‐year period,
which is reassuring.3 Furthermore, while absence of delays in recording
and receiving data is the ideal scenario, it is unlikely that delays in
recording can be changed as result of direct action by data providers.
Finally, this work is based on a single vaccine/outcome pair. Neverthe-
less, results for other vaccine/outcome pairs are likely to be similar to
the ones observed for seasonal influenza/GBS. The reason for this is
twofold: first and as explained above, the lack of improvement in the
system's performance is probably related to the fact that the perfor-
mance is assessed at the end of the surveillance period (when most of
the data have already accrued); second, delays in receiving data are
fixed and similar for all outcomes. Regarding delays in recording out-
comes, GBS is likely to have longer delays than other conditions due
to prolonged hospitalisation. Therefore, removing delays in recording
these other outcomeswould result in even less improvement on power.
In conclusion, minimising delays in data availability are unlikely to
substantially improve the performance of a system using CPRD data.
Expansion of the data is required.
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